Remifentanil Noridem 2mg Powder For Concentrate For Solution For Injection Or Infusion
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Remifentanil Noridem 2 mg Powder for Concentrate for Solution for Injection or Infusion
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Remifentanil powder for concentrate for solution for injection or infusion is available in glass vials containing 2 mg of remifentanil base (as remifentanil hydrochloride).
When reconstituted as directed, solutions of Remifentanil Noridem are clear and colourless and contain 1mg/ml of remifentanil base as remifentanil hydrochloride.
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Powder for concentrate for solution for injection or infusion
Sterile, endotoxin-free, preservative-free, white to off white, lyophilized powder, to be reconstituted before use.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Remifentanil is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia.
Remifentanil is indicated for provision of analgesia in mechanically ventilated intensive care patients 18 years of age and over
4.2 Posology and method of administration
Remifentanil should be administered only in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function and by persons specifically trained in the use of anaesthetic drugs and the recognition and management of the expected adverse effects of potent opioids, including respiratory and cardiac resuscitation. Such training must include the establishment and maintenance of a patent airway and assisted ventilation.
Continuous infusions of Remifentanil must be administered by a calibrated infusion device into a fast flowing IV line or via a dedicated IV line. This infusion line should be connected at, or close to, the venous cannula and primed, to minimise the potential dead space (see section 6.6 for additional information, including tables with examples of infusion rates by body weight to help titrate Remifentanil to the patient's anaesthetic needs).
Remifentanil may also be given by target controlled infusion (TCI) with an approved infusion device incorporating the Minto pharmacokinetic model with covariates for
age and lean body mass (LBM).
Care should be taken to avoid obstruction or disconnection of infusion lines and to adequately clear the lines to remove residual Remifentanil after use (see section 4.4). Remifentanil is for intravenous use only and must not be administered by epidural or intrathecal injection (see section 4.3).
Dilution
Remifentanil may be further diluted after reconstitution (see section 6.4 and 6.6 for storage conditions of the reconstituted/diluted product and the recommended diluents).
For manually-controlled infusion Remifentanil can be diluted to concentrations of 20 to 250 micrograms/ml (50 micrograms/ml is the recommended dilution for adults and 20 to 25 micrograms/ml for paediatric patients aged 1 year and over).
For TCI the recommended dilution of Remifentanil is 20 to 50 micrograms/ml. (See Section 6.6 Instructions for use/handling for additional information, including tables to help titrate Remifentanil to the patient's anaesthetic needs).
4.2.1 General Anaesthesia
The administration of Remifentanil must be individualised based on the patient's response. Specific dosing guidelines for patients undergoing cardiac surgery are provided in section 4.2.2 below.
4.2.1.1. Adults
Administration by Manually-Controlled Infusion
The following table summarises the starting infusion rates and dose range:
DOSING GUIDELINES FOR ADULTS
|
INDICATION |
BOLUS INJECTION (micrograms/kg) |
CONTINUOUS INFUSION (micrograms/kg/min) | |
|
Starting Rate |
Range | ||
|
Induction of anaesthesia |
1(give over not less than 30 seconds) |
0.5 to 1 |
- |
|
Maintenance of anaesthesia in ventilated patients | |||
|
• Nitrous oxide (66%) |
0.5 to 1 |
0.4 |
0.1 to 2 |
|
• Isoflurane (starting dose 0.5MAC) |
0.5 to 1 |
0.25 |
0.05 to 2 |
|
• Propofol (Starting dose |
0.5 to 1 |
0.25 |
0.05 to 2 |
|
100 micrograms/kg/min) |
When given by bolus injection at induction Remifentanil should be administered over not less than 30 seconds.
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid an increase of haemodynamic effects such as hypotension and bradycardia (see Concomitant medication below).
Induction of anaesthesia: Remifentanil should be administered with a standard dose of an hypnotic agent, such as propofol, thiopentone, or isoflurane, for the induction of anaesthesia. Administering Remifentanil after an hypnotic agent will reduce the incidence of muscle rigidity. Remifentanil can be administered at an infusion rate of 0.5 to 1 micrograms/kg/min, with or without an initial slow bolus injection of 1 microgram/kg given over not less than 30 seconds. If endotracheal intubation is to occur more than 8 to 10 minutes after the start of the infusion of Remifentanil, then a bolus injection is not necessary.
Maintenance of anaesthesia in ventilated patients: After endotracheal intubation, the infusion rate of Remifentanil should be decreased, according to anaesthetic technique, as indicated in the above table. Due to the fast onset and short duration of action of Remifentanil, the rate of administration during anaesthesia can be titrated upward in 25% to 100% increments or downward in 25% to 50% decrements, every 2 to 5 minutes to attain the desired level of p-opioid response. In response to light anaesthesia, supplemental slow bolus injections may be administered every 2 to 5 minutes.
Anaesthesia in spontaneously breathing anaesthetised patients with a secured airway (e.g. laryngeal mask anaesthesia): In spontaneously breathing anaesthetised patients with a secured airway respiratory depression is likely to occur. Special care is needed to adjust the dose to the patient requirements and ventilatory support may be required. The recommended starting infusion rate for supplemental analgesia in spontaneously breathing anaesthetised patients is 0.04 micrograms/kg/min with titration to effect. A range of infusion rates from 0.025 to 0.1 micrograms/kg/min has been studied. Bolus injections are not recommended in spontaneously breathing anaesthetised patients.
Remifentanil should not be used as an analgesic in procedures where patients remain conscious or do not receive any airway support during the procedure.
Concomitant medication: Remifentanil decreases the amounts or doses of inhaled anaesthetics, hypnotics and benzodiazepines required for anaesthesia (see Section 4.5 Interaction with other medicaments and other forms of interaction).
Doses of the following agents used in anaesthesia: isoflurane, thiopentone, propofol and temazepam have been reduced by up to 75% when used concurrently with remifentanil.
Guidelines for discontinuation/continuation into the immediate post-operative period: Due to the very rapid offset of action of Remifentanil no residual opioid activity will be present within 5 to 10 minutes after discontinuation. For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of Remifentanil. Sufficient time must be allowed to reach the maximum effect of the longer acting analgesic.
The choice of analgesic should be appropriate for the patient's surgical procedure and the level of post-operative care.
Care should be taken to avoid inadvertent administration of Remifentanil remaining in IV lines and cannulae (see section 4.4 Special warnings and precautions for use).
In the event that longer acting analgesia has not been established prior to the end of surgery, Remifentanil may need to be continued to maintain analgesia during the immediate post-operative period until longer acting analgesia has reached its maximum effect.
Guidance on provision of analgesia and sedation in mechanically ventilated intensive care patients is provided in section 4.2.3 below.
In patients who are breathing spontaneously, the infusion rate of Remifentanil should initially be decreased to a rate of 0.1 micrograms/kg/min. The infusion rate may then be increased or decreased by not greater than 0.025 micrograms/kg/min every five minutes, to balance the patient's level of analgesia and respiratory rate. Remifentanil should only be used in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function, under the close supervision of persons specifically trained in the recognition and management of the respiratory effects of potent opioids.
The use of bolus injections of Remifentanil to treat pain during the post-operative period is not recommended in patients who are breathing spontaneously.
Administration by Target-Controlled Infusion
Induction and maintenance of anaesthesia in ventilated patients: Remifentanil TCI should be used in association with an intravenous or inhalational hypnotic agent during the induction and maintenance of anaesthesia in ventilated adult patients (see the table in Dosing Guidelines For Adults under 4.2.1.1). In association with these agents, adequate analgesia for induction of anaesthesia and surgery can generally be achieved with target blood remifentanil concentrations ranging from 3 to 8 nanograms/ml. Remifentanil should be titrated to individual patient response. For particularly stimulating surgical procedures target blood concentrations up to 15 nanograms/ml may be required.
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid an increase of haemodynamic effects such as hypotension and bradycardia (see Table and Concomitant medication subsection in 4.2.1.1).
For information on blood remifentanil concentrations achieved with manually-controlled infusion see Table 6.
There are insufficient data to make recommendations on the use of TCI for spontaneous ventilation anaesthesia.
Guidelines for discontinuation/continuation into the immediate post-operative period: At the end of surgery when the TCI infusion is stopped or the target concentration reduced, spontaneous respiration is likely to return at calculated remifentanil concentrations in the region of 1 to 2 nanograms/ml. As with manually-controlled infusion, post-operative analgesia should be established before the end of surgery with longer acting analgesics (see Guidelines for discontinuation under Administration by manually-controlled infusion in section 4.2.1.1)
As there are insufficient data, the administration of Remifentanil by TCI for the management of post-operative analgesia is not recommended.
4.2.1.2 Paediatric patients (1 to 12 years of age)
Co-administration of Remifentanil and an intravenous anaesthetic agent for induction
of anaesthesia has not been studied in detail and is therefore not recommended. Remifentanil TCI has not been studied in paediatric patients and therefore administration of Remifentanil by TCI is not recommended in these patients.
When given by bolus injection Remifentanil should be administered over not less than 30 seconds. Surgery should not commence until at least 5 minutes after the start of the Remifentanil infusion, if a simultaneous bolus dose has not been given. For sole administration of nitrous oxide (70%) with Remifentanil, typical maintenance infusion rates should be between 0.4 and 3 micrograms/kg/min, and although not specifically studied, adult data suggest that 0.4 micrograms/kg/min is an appropriate starting rate. Paediatric patients should be monitored and the dose titrated to the depth of analgesia appropriate for the surgical procedure.
Induction of anaesthesia: The use of remifentanil for induction of anaesthesia in patients aged 1 to 12 years is not recommended as there are no data available in this patient population.
Maintenance of anaesthesia: The following doses of Remifentanil are recommended for maintenance of anaesthesia:
DOSING GUIDELINES FOR PAEDIATRIC PATIENTS (1 to12 years of age)
|
*CONCOMITANT ANAESTHETIC AGENT |
BOLUS INJECTION (micrograms/kg) |
CONTINUOUS INFUSION (micrograms/kg/min) | |
|
Starting Rate |
Range | ||
|
Halothane (starting dose 0.3MAC) |
1 |
0.25 |
0.05 to 1.3 |
|
Sevoflurane (starting dose 0.3MAC) |
1 |
0.25 |
0.05 to 0.9 |
|
Isoflurane (starting dose 0.5MAC) |
1 |
0.25 |
0.06 to 0.9 |
*co-administered with nitrous oxide/oxygen in a ratio of 2:1
Concomitant medication: At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane, halothane and sevoflurane should be administered as recommended above to avoid an increase of haemodynamic effects such as hypotension and bradycardia. No data are available for dosage recommendations for simultaneous use of other hypnotics other than those listed in the table with remifentanil (see section 4.2.1.1 Adults-Concomitant medication).
Guidelines for patient management in the immediate post-operative period/ Establishment of alternative analgesia prior to discontinuation of Remifentanil:
Due to the very rapid offset of action of Remifentanil, no residual activity will be present within 5 to 10 minutes after discontinuation. For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of Remifentanil. Sufficient time must be allowed to reach the therapeutic effect of the longer acting analgesic. The choice of agent(s), the dose and the time of administration should be planned in advance and individually tailored to be appropriate for the patient's surgical procedure and the level of post-operative care anticipated (see section 4.4. Special warnings and precautions for use).
4.2.1.3 Neonates/infants (aged less than 1 year):
There is limited clinical trial experience of remifentanil in neonates and infants (aged under 1 year old; see section 5.1). The pharmacokinetic profile of remifentanil in neonates/infants (aged less than 1 year) is comparable to that seen in adults after correction for body weight differences. (see section 5.2.). However, because there are insufficient clinical data, the administration of Remifentanil is not recommended for this age group.
Use for Total Intravenous anaesthesia (TIVA): There is limited clinical trial experience of remifentanil for TIVA in infants (see section 5.1). However, there are insufficient clinical data to make dosage recommendations.
4.2.2 Cardiac anaesthesia
Administration by Manually-Controlled Infusion DOSING GUIDELINES FOR CARDIAC ANAESTHESIA
|
INDICATION |
BOLUS INJECTION (micrograms/kg) |
CONTINUOUS INFUSION (micrograms/kg/min) | |
|
Starting Rate |
Range | ||
|
Induction of anaesthesia |
Not recommended |
1 |
- |
|
Maintenance of anaesthesia in ventilated patients: | |||
|
• Isoflurane (starting dose 0.4MAC) |
0.5 to 1 |
1 |
0.003 to 4 |
|
• Propofol (Starting dose 50 micrograms/kg/min) |
0.5 to 1 |
1 |
0.01 to 4.3 |
|
Continuation of postoperative analgesia, prior to extubation |
Not recommended |
1 |
0 to 1 |
Induction period of anaesthesia: After administration of hypnotic to achieve loss of consciousness, Remifentanil should be administered at an initial infusion rate of 1 microgram/kg/min. The use of bolus injections of Remifentanil during induction in cardiac surgical patients is not recommended. Endotracheal intubation should not occur until at least 5 minutes after the start of the infusion.
Maintenance period of anaesthesia: After endotracheal intubation the infusion rate of Remifentanil can be titrated upward in 25% to 100% increments, or downward in 25% to 50% decrements, every 2 to 5 minutes according to patient need. Supplemental slow bolus doses, administered over not less than 30 seconds, may also be given every 2 to 5 minutes as required. High risk cardiac patients, such as those with poor ventricular function or undergoing valve surgery, should be administered a maximum bolus dose of 0.5 micrograms/kg. These dosing recommendations also apply during hypothermic cardiopulmonary bypass (see section 5.2 Pharmacokinetic properties - Cardiac anaesthesia).
Concomitant medication: At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid excessive depth of anaesthesia. No data are available for dosage recommendations for simultaneous use of other hypnotics other than those listed in the table with remifentanil (see section 4.2.1.1 Adults - Concomitant medication).
Guidelines for post-operative patient management
Continuation of Remifentanil post-operatively to provide analgesia prior to weaning for extubation: It is recommended that the infusion of Remifentanil should be maintained at the final intra-operative rate during transfer of patients to the postoperative care area. Upon arrival into this area, the patient's level of analgesia and sedation should be closely monitored and the Remifentanil infusion rate adjusted to meet the individual patient's requirements (see section 4.2.3 for further information on management of intensive care patients).
Establishment of alternative analgesia prior to discontinuation of Remifentanil:
Due to the very rapid offset of action of Remifentanil, no residual opioid activity will be present within 5 to 10 minutes after discontinuation. Prior to discontinuation of Remifentanil, patients must be given alternative analgesic and sedative agents at a sufficient time in advance to allow the therapeutic effects of these agents to become established. It is therefore recommended that the choice of agent(s), the dose and the time of administration are planned, before weaning the patient from the ventilator.
Guidelines for discontinuation of Remifentanil: Due to the very rapid offset of action of Remifentanil, hypertension, shivering and aches have been reported in cardiac patients immediately following discontinuation of Remifentanil (see section 4.8 Undesirable effects). To minimise the risk of these occurring, adequate alternative analgesia must be established (as described above), before the Remifentanil infusion is discontinued. The infusion rate should be reduced by 25% decrements in at least 10-minute intervals until the infusion is discontinued. During weaning from the ventilator the Remifentanil infusion should not be increased and only down titration should occur, supplemented as required with alternative analgesics. Haemodynamic changes such as hypertension and tachycardia should be treated with alternative agents as appropriate.
When other opioid agents are administered as part of the regimen for transition to alternative analgesia, the patient must be carefully monitored. The benefit of providing adequate post-operative analgesia must always be balanced against the potential risk of respiratory depression with these agents.
Administration by Target-Controlled Infusion
Induction and maintenance of anaesthesia: Remifentanil TCI should be used in
association with an intravenous or inhalational hypnotic agent during the induction and maintenance of anaesthesia in ventilated adult patients (see table in Dosing Guidelines for Cardiac Anaesthesia under 4.2.2). In association with these agents, adequate analgesia for cardiac surgery is generally achieved at the higher end of the range of target blood remifentanil concentrations used for general surgical procedures. Following titration of remifentanil to individual patient response, blood concentrations as high as 20 nanograms/ml have been used in clinical studies. At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid an increase of haemodynamic effects such as hypotension and bradycardia (see Table and Concomitant medication subsection in 4.2.2).
For information on blood remifentanil concentrations achieved with manually-controlled infusion see Table 6.
Guidelines for discontinuation/continuation into the immediate post-operative period: At the end of surgery when the TCI infusion is stopped or the target concentration reduced, spontaneous respiration is likely to return at calculated remifentanil concentrations in the region of 1 to 2 nanograms/ml. As with manually-controlled infusion, post-operative analgesia should be established before the end of surgery with longer acting analgesics (see Guidelines for discontinuation under Administration by manually-controlled infusion in section 4.2.2.)
As there are insufficient data, the administration of Remifentanil by TCI for the management of post-operative analgesia is not recommended.
4.2.3 Use in Intensive Care
Remifentanil can be used for the provision of analgesia in mechanically ventilated intensive care patients. Sedative agents should be added as appropriate.
Remifentanil has been studied in mechanically ventilated intensive care patients in well controlled clinical trials for up to three days. As patients were not studied beyond three days, no evidence of safety and efficacy for longer treatment has been established. Therefore, the use of Remifentanil is not recommended for a duration of treatment greater than 3 days.
Remifentanil TCI has not been studied in intensive care patients and therefore administration Remifentanil by TCI is not recommended in these patients.
In adults, it is recommended that Remifentanil is initiated at an infusion rate of 0.1 micrograms/kg/min (6 micrograms/kg/h) to 0.15 micrograms/kg/min (9
micrograms/kg/h). The infusion rate should be titrated in increments of 0.025 micrograms/kg/min (1.5 micrograms/kg/h) to achieve the desired level of sedation and analgesia. A period of at least 5 minutes should be allowed between dose adjustments. The level of sedation and analgesia should be carefully monitored, regularly reassessed and the Remifentanil infusion rate adjusted accordingly. If an infusion rate of 0.2 micrograms/kg/min (12 micrograms/kg/h) is reached and the desired level of sedation is not achieved, it is recommended that dosing with an appropriate sedative agent is initiated (see below). The dose of sedative agent should be titrated to obtain the desired level of sedation. Further increases to the Remifentanil infusion rate in increments of 0.025 micrograms/kg/min (1.5 micrograms/kg/h) may be made if additional analgesia is required.
The following table summarises the starting infusion rates and typical dose range for provision of analgesia and sedation in individual patients:
DOSING GUIDELINES FOR USE OF REMIFENTANIL WITHIN THE INTENSIVE CARE SETTING
|
CONTINUOUS INFUSION micrograms/kg/min (micrograms/kg/h) | |
|
Starting Rate |
Range |
|
0.1 (6) to 0.15 (9) |
0.006 (0.36) to 0.74 (44.4) |
Bolus doses of Remifentanil are not recommended in the intensive care setting.
The use of Remifentanil will reduce the dosage requirement of any concomitant sedative agents. Typical starting doses for sedative agents, if required, are given below:
RECOMMENDED STARTING DOSE OF SEDATIVE AGENTS, IF REQUIRED
|
Sedative |
Bolus |
Infusion |
|
Agent |
(mg/kg) |
(mg/kg/h) |
|
Propofol |
Up to 0.5 |
0.5 |
|
Midazolam |
Up to 0.03 |
0.03 |
To allow separate titration of the respective agents, sedative agents should not be administered as an admixture.
Additional analgesia for ventilated patients undergoing stimulating procedures:
An increase in the existing Remifentanil infusion rate may be required to provide additional analgesic cover for ventilated patients undergoing stimulating and/or painful procedures such as endotracheal suctioning, wound dressing and physiotherapy. It is recommended that an Remifentanil infusion rate of at least 0.1 micrograms/kg/min (6 micrograms/kg/h) should be maintained for at least 5 minutes prior to the start of the stimulating procedure. Further dose adjustments may be made every 2 to 5 minutes in increments of 25%-50% in anticipation of, or in response to, additional requirement for analgesia. A mean infusion rate of 0.25 micrograms/kg/min (15 micrograms/kg/h), maximum 0.75 micrograms/kg/min (45 micrograms/kg/h), has been administered for provision of additional analgesia during stimulating procedures.
Establishment of alternative analgesia prior to discontinuation of Remifentanil:
Due to the very rapid offset of action of Remifentanil, no residual opioid activity will be present within 5 to 10 minutes after discontinuation regardless of the duration of infusion. Following administration of Remifentanil, the possibility of tolerance and hyperalgesia should be considered. Therefore, prior to discontinuation of Remifentanil, patients must be given alternative analgesic and sedative agents to prevent hyperalgesia and associated haemodynamic changes. These agents must be given at a sufficient time in advance to allow the therapeutic effects of these agents to become established. The range of options for analgesia includes long acting oral, intravenous, or regional analgesics controlled by the nurse or the patient. These techniques should always be titrated to individual patient needs as the infusion of Remifentanil is reduced. It is recommended that the choice of agent(s), the dose, and the time of administration are planned prior to discontinuation of Remifentanil.
There is a potential for the development of tolerance with time during prolonged administration of p-opioid agonists.
Guidelines for extubation and discontinuation of Remifentanil: In order to ensure a smooth emergence from a Remifentanil-based regimen it is recommended that the infusion rate of Remifentanil is titrated in stages to 0.1 micrograms/kg/min (6 micrograms/kg/h) over a period up to 1 hour prior to extubation.
Following extubation, the infusion rate should be reduced by 25% decrements in at least 10-minute intervals until the infusion is discontinued. During weaning from the ventilator the Remifentanil infusion should not be increased and only down titration should occur, supplemented as required with alternative analgesics.
Upon discontinuation of Remifentanil, the IV cannula should be cleared or removed to prevent subsequent inadvertent administration.
When other opioid agents are administered as part of the regimen for transition to alternative analgesia, the patient must be carefully monitored. The benefit of providing adequate analgesia must always be balanced against the potential risk of respiratory depression.
4.2.3.1 Paediatric intensive care patients
The use of remifentanil in intensive care patients under the age of 18 years is not recommended as there are no data available in this patient population.
4.2.3.2 Renally-impaired intensive care patients
No adjustments to the doses recommended above are necessary in renally-impaired patients, including those undergoing renal replacement therapy; however the clearance of the carboxylic acid metabolite is reduced in patients with renal impairment (see Section 5.2 Pharmacokinetic properties).
4.2.4 Special patient populations 4.2.4.1. Elderly (over 65 years of age)
General anaesthesia: The initial starting dose of remifentanil administered to patients over 65 should be half the recommended adult dose and then shall be titrated to individual patient need as an increased sensitivity to the pharmacological effects of remifentanil has been seen in this patient population. This dose adjustment applies to use in all phases of anaesthesia including induction, maintenance, and immediate post-operative analgesia.
Because of the increased sensitivity of elderly patients to Remifentanil, when administering Remifentanil by TCI in this population the initial target concentration should be 1.5 to 4 ng/ml with subsequent titration to response.
Cardiac anaesthesia: No initial dose reduction is required (see section 4.2.2.). Intensive Care: No initial dose reduction is required (see section 4.2.3.).
4.2.4.2 Obese patients
For manually-controlled infusion it is recommended that for obese patients the dosage of Remifentanil should be reduced and based upon ideal body weight as the clearance and volume of distribution of remifentanil are better correlated with ideal body weight than actual body weight.
With the calculation of lean body mass (LBM) used in the Minto model, LBM is
likely to be underestimated in female patients with a body mass index (BMI) greater 2 2 than 35 kg/m and in male patients with BMI greater than 40 kg/m . To avoid
underdosing in these patients, remifentanil TCI should be titrated carefully to
individual response.
4.2.4.3 Renal impairment
On the basis of investigations carried out to date, a dose adjustment in patients with impaired renal function, including intensive care patients, is not necessary.
4.2.4.4. Hepatic impairment
Studies carried out with a limited number of patients with impaired liver function, do not justify any special dosage recommendations. However, patients with severe hepatic impairment may be slightly more sensitive to the respiratory depressant effects of remifentanil (see section 4.4). These patients shall be closely monitored and the dose of remifentanil shall be titrated to individual patient need.
4.2.4.5 Neurosurgery
Limited clinical experience in patients undergoing neurosurgery has shown that no special dosage recommendations are required.
4.2.4.6 ASA III/IV patients
General anaesthesia: As the haemodynamic effects of potent opioids can be expected to be more pronounced in ASA III/IV patients, caution should be exercised in the administration of Remifentanil in this population. Initial dosage reduction and subsequent titration to effect is therefore recommended. In paediatric patients, there are insufficient data to make a dosage recommendation.
For TCI, a lower initial target of 1.5 to 4 nanograms/ml should be used in ASA III or IV patients and subsequently titrated to response.
Cardiac anaesthesia: No initial dose reduction is required (see section 4.2.2).
4.3 Contraindications
As glycine is present in the formulation, Remifentanil is contra-indicated for epidural and intrathecal use.
Remifentanil is contra-indicated in patients with known hypersensitivity to any component of the preparation and other fentanyl analogues.
Remifentanil is contra-indicated for use as the sole agent for induction of anaesthesia.
4.4 Special warnings and precautions for use
Remifentanil should be administered only in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function, and by persons specifically trained in the use of anaesthetic drugs and the recognition and management of the expected adverse effects of potent opioids, including respiratory and cardiac resuscitation. Such training must include the establishment and maintenance of a patent airway and assisted ventilation. The use of Remifentanil in mechanically ventilated intensive care patients is not recommended for a duration of treatment greater than 3 days.
Rapid offset of action /Transition to alternative analgesia
Due to the very rapid offset of action of Remifentanil, no residual opioid
activity will be present within 5 to 10 minutes after the discontinuation of
Remifentanil. For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of Remifentanil. The possibility of tolerance, hyperalgesia and associated haemodynamic changes should be considered when used in Intensive Care Unit. Prior to discontinuation of Remifentanil, patients must be given alternative analgesic and sedative agents. Sufficient time must be allowed to reach the therapeutic effect of the longer acting analgesic. The choice of agent(s), the dose and the time of administration should be planned in advance and individually tailored to be appropriate for the patient's surgical procedure and the level of post-operative care anticipated. When other opioid agents are administered as part of the regimen for transition to alternative analgesia, the benefit of providing adequate post-operative analgesia must always be balanced against the potential risk of respiratory depression with these agents.
Discontinuation of Treatment
Symptoms following withdrawal of Remifentanil including tachycardia, hypertension and agitation have been reported infrequently upon abrupt cessation, particularly after prolonged administration of more than 3 days. Where reported, re-introduction and tapering of the infusion has been beneficial. The use of Remifentanil in mechanically ventilated intensive care patients is not recommended for duration of treatment greater than 3 days.
Inadvertent administration
A sufficient amount of Remifentanil may be present in the dead space of the IV line and/or cannula to cause respiratory depression, apnoea and/or muscle rigidity if the line is flushed with IV fluids or other drugs. This may be avoided by administering Remifentanil into a fast flowing IV line or via a dedicated IV line which is removed when Remifentanil is discontinued.
Muscle rigidity - prevention and management
At the doses recommended muscle rigidity may occur. As with other opioids, the incidence of muscle rigidity is related to the dose and rate of administration. Therefore, bolus injections should be administered over not less than 30 seconds.
Muscle rigidity induced by remifentanil must be treated in the context of the patient's clinical condition with appropriate supporting measures including ventilatory support. Excessive muscle rigidity occurring during the induction of anaesthesia should be treated by the administration of a neuromuscular blocking agent and/or additional hypnotic agents. Muscle rigidity seen during the use of remifentanil as an analgesic may be treated by stopping or decreasing the rate of administration of remifentanil. Resolution of muscle rigidity after discontinuing the infusion of remifentanil occurs within minutes. Alternatively an opioid antagonist may be administered, however this may reverse or attenuate the analgesic effect of remifentanil.
Respiratory depression - prevention and management
As with all potent opioids, profound analgesia is accompanied by marked respiratory depression. Therefore, remifentanil should only be used in areas where facilities for monitoring and dealing with respiratory depression are available. The appearance of respiratory depression should be managed appropriately, including decreasing the rate of infusion by 50%, or by a temporary discontinuation of the infusion. Unlike other fentanyl analogues, remifentanil has not been shown to cause recurrent respiratory depression even after prolonged administration. However, as many factors may affect post-operative recovery it is important to ensure that full consciousness and adequate spontaneous ventilation are achieved before the patient is discharged from the recovery area.
Cardiovascular effects
The risk of cardiovascular effects such as hypotension and bradycardia (see section 4.8 Undesirable Effects), which may rarely lead to asystole/cardiac arrest may be reduced by lowering the rate of infusion of Remifentanil or the dose of concurrent anaesthetics or by using IV fluids, vasopressor or anticholinergic agents as appropriate.
Debilitated, hypovolaemic, and elderly patients may be more sensitive to the cardiovascular effects of remifentanil.
Neonates/infants
There is limited data available on use in neonates/infants under 1 year of age (see sections 4.2.1.3. and 5.1).
Drug abuse
As with other opioids remifentanil may produce dependency.
4.5 Interaction with other medicinal products and other forms of interaction
Remifentanil is not metabolised by plasmacholinesterase, therefore, interactions with drugs metabolised by this enzyme are not anticipated.
As with other opioids, remifentanil, whether given by manually-controlled infusion or TCI, decreases the amounts or doses of inhaled and IV anaesthetics, and benzodiazepines required for anaesthesia (see section 4.2 Posology and method of administration, General Anaesthesia - Adults, Paediatric Patients, and Cardiac Surgery). If doses of concomitantly administered CNS depressant drugs are not reduced, patients may experience an increased incidence of adverse effects associated with these agents.
The cardiovascular effects of Remifentanil (hypotension and bradycardia), may be exacerbated in patients receiving concomitant cardiac depressant drugs, such as beta-blockers and calcium channel blocking agents.
4.6 Fertility, pregnancy and lactation
There are no adequate and well-controlled studies in pregnant women. Remifentanil should be
used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
It is not known whether remifentanil is excreted in human milk. However, because fentanyl
analogues are excreted in human milk and remifentanil-related material was found in rat milk
after dosing with remifentanil, nursing mothers should be advised to discontinue breast
feeding for 24 hours following administration of remifentanil.
For a summary of the reproductive toxicity study findings please refer to Section 5.3.
Preclinical safety data.
Labour and delivery
There are insufficient data to recommend remifentanil for use during labour and caesarean section. It is known that remifentanil crosses the placental barrier and fentanyl analogues can cause respiratory depression in the child.
4.7 Effects on ability to drive and use machines
After anaesthesia with remifentanil the patient should not drive or operate machinery. The physician should decide when these activities may be resumed. It is advisable that the patient is accompanied when returning home and that alcoholic drink is avoided.
4.8 Undesirable effects
The most common undesirable effects associated with remifentanil are direct extensions of p-opioid agonist pharmacology. These adverse events resolve within minutes of discontinuing or decreasing the rate of remifentanil administration. The frequencies below are defined as very common 1/10), common 1/100 to <1/10), uncommon ( ^ 1/1,000 to <1/100), rare ( ^ 1/10,000 to <1/1,000) and very rare (<1/10,000), not known (cannot be estimated from the available data).
Immune System Disorders
Rare: Allergic reactions including anaphylaxis have been reported in patients
receiving remifentanil in conjunction with one or more anaesthetic agents.
Psychiatric disorders
Not known: Drug dependence
Nervous System Disorders Very Skeletal muscle rigidity
common:
Rare: Sedation (during recovery from general anaesthesia)
Not known: Convulsions
Cardiac Disorders
Common: Bradycardia
Rare: Asystole/cardiac arrest, usually preceded by bradycardia, has been
reported in patients receiving remifentanil in conjunction with other anaesthetic agents.
Not known: Atrioventricular block
Vascular Disorders
Very Hypotension
common:
Common: Post-operative hypertension
Respiratory, Thoracic and Mediastinal Disorders
Common: Acute respiratory depression, apnoea Uncommon: Hypoxia
Gastrointestinal Disorders
Very Nausea, vomiting
common:
Uncommon: Constipation
Skin and Subcutaneous Tissue Disorders
Common: Pruritus
General Disorders and Administration Site Conditions
Common: Post-operative shivering Uncommon: Post-operative aches Not known: Drug tolerance
Discontinuation of treatment
Symptoms following withdrawal of remifentanil including tachycardia, hypertension and agitation have been reported infrequently upon abrupt cessation, particularly after prolonged administration of more than 3 days (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via
Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard.
4.9 Overdose
As with all potent opioid analgesics, overdose would be manifested by an extension of the pharmacologically predictable actions of remifentanil. Due to the very short duration of action of Remifentanil, the potential for deleterious effects due to overdose is limited to the immediate time period following drug administration. Response to discontinuation of the drug is rapid, with return to baseline within ten minutes.
In the event of overdose, or suspected overdose, take the following actions: discontinue administration of Remifentanil, maintain a patent airway, initiate assisted or controlled ventilation with oxygen, and maintain adequate cardiovascular function. If depressed respiration is associated with muscle rigidity, a neuromuscular blocking agent may be required to facilitate assisted or controlled respiration. Intravenous fluids and vasopressor agents for the treatment of hypotension and other supportive measures may be employed.
Intravenous administration of an opioid antagonist such as naloxone may be given as a specific antidote in addition to ventilatory support to manage severe respiratory depression. The duration of respiratory depression following overdose with Remifentanil is unlikely to exceed the duration of action of the opioid antagonist.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Opioid anaesthetic, ATC code: N01AH06 Remifentanil is a selective p-opioid agonist with a rapid onset and very short duration of action. The p-opioid activity, of remifentanil, is antagonised by narcotic antagonists, such as naloxone.
Assays of histamine in patients and normal volunteers have shown no elevation in histamine levels after administration of remifentanil in bolus doses up to 30 micrograms/kg.
Neonates/infants (aged less than 1 year):
In a randomised (ratio of 2:1, remifentanil :halothane), open label, parallel group, multicentre study in 60 young infants and neonates ^ 8 weeks of age (mean 5.5 weeks) with an ASA physical status of I-II who were undergoing pyloromyotomy, the efficacy and safety of remifentanil (given as a 0.4 pg/kg/min initial continuous infusion plus supplemental doses or infusion rate changes as needed) was compared with halothane (given at 0.4% with supplemental increases as needed). Maintenance of anaesthesia was achieved by the additional administration of 70% nitrous oxide (N20) plus 30% oxygen. Recovery times were superior in the remifentanil relative to the halothane groups (not significant).
Use for Total Intravenous anaesthesia (TIVA) - children aged 6 months to 16 years
TIVA with remifenanil in paediatric surgery was compared to inhalation anaesthesia in three randomised, open-label studies. The results are summarised in the table below.
|
Surgical intervention |
Age (y), (N) |
Study condition (maintenance) |
Extubation (min) (mean (SD)) |
|
Lower abdominal/urological surgery |
TIVA: propofol (5 - 10 mg/kg/h) + remifentanil (0.125 - 1.0 bg/kg/min) |
11.8 (4.2) | |
|
0.5-16 (120) |
Inhalation anaesthesia: sevoflurane (1.0 -1.5 MAC) and remifentanil (0.125 - 1.0 bg/kg/min) |
15.0 (5.6) (p<0.05) | |
|
4-11 (50) |
TIVA: propofol (3 mg/kg/h) + remifentanil (0.5 bg/kg/min) |
11 (3.7) | |
|
ENT-surgery |
Inhalation anaesthesia: desflurane (1.3 MAC) and N2O mixture |
9.4 (2.9) Not significant | |
|
General or ENT surgery |
2-12 (153) |
TIVA: remifentanil (0.2 - 0.5 bg/kg/min) + propofol (100 - 200 bg/kg/min) |
Comparable extubation times |
|
Inhalation anaesthesia: sevoflurane (1 - 1.5 MAC) + N2O mixture |
(based on limited data) |
In the study in lower abdominal/urological surgery comparing remifentanil/propofol with remifentanil/sevoflurane, hypotension occurred significantly more often under remifentanil/sevoflurane, and bradycardia occurred significantly more often under remifentanil/propofol. In the study in ENT surgery comparing remifentanil/propofol with desflurane/nitrous oxide, a significantly higher heart rate was seen in subjects receiving desflurane/nitrous oxide compared with remifentanil/propofol and with baseline values.
5.2 Pharmacokinetic properties
Following administration of the recommended doses of remifentanil, the effective biological half-life is 3-10 minutes. The average clearance of remifentanil in young healthy adults is 40ml/min/kg, the central volume of distribution is 100ml/kg and the steady-state volume of distribution is 350ml/kg. In children aged 1 to 12 years, remifentanil clearance and volume of distribution decreases with increasing age; the values of these parameters in neonates are approximately twice those of healthy young adults.
Blood concentrations of remifentanil are proportional to the dose administered throughout the recommended dose range. For every 0.1 micrograms/kg/min increase in infusion rate, the blood concentration of remifentanil will rise 2.5 nanograms/ml. Remifentanil is approximately 70% bound to plasma proteins.
Metabolism
Remifentanil is an esterase metabolised opioid that is susceptible to metabolism by non-specific blood and tissue esterases. The metabolism of remifentanil results in the formation of an essentially inactive carboxylic acid metabolite (1/4600th as potent as remifentanil). The half life of the metabolite in healthy adults is 2 hours. Approximately 95% of remifentanil is recovered in the urine as the carboxylic acid metabolite. Remifentanil is not a substrate for plasma cholinesterase.
Cardiac anaesthesia
The clearance of remifentanil is reduced by approximately 20% during hypothermic (28°C) cardiopulmonary bypass. A decrease in body temperature lowers elimination clearance by 3% per degree centigrade.
Renal impairment
The rapid recovery from remifentanil-based sedation and analgesia is unaffected by renal status.
The pharmacokinetics of remifentanil are not significantly changed in patients with varying degrees of renal impairment even after administration for up to 3 days in the intensive care setting.
The clearance of the carboxylic acid metabolite is reduced in patients with renal impairment. In intensive care patients with moderate/severe renal impairment, the concentration of the carboxylic acid metabolite is expected to reach approximately 100-fold the level of remifentanil at steady-state. Clinical data demonstrate that the accumulation of the metabolite does not result in clinically relevant g-opioid effects even after administration of remifentanil infusions for up to 3 days in these patients.
There is no evidence that remifentanil is extracted during renal replacement therapy.
The carboxylic acid metabolite is extracted during haemodialysis by 25 - 35 %.
Hepatic impairment
The pharmacokinetics of remifentanil are not changed in patients with severe hepatic impairment awaiting liver transplant, or during the anhepatic phase of liver transplant surgery. Patients with severe hepatic impairment may be slightly more sensitive to the respiratory depressant effects of remifentanil. These patients should be closely monitored and the dose of remifentanil should be titrated to the individual patient need.
Paediatric patients
The average clearance and steady state volume of distribution of remifentanil are increased in younger children and decline to young healthy adult values by age 17. The elimination half-life of remifentanil in neonates is not significantly different from that of young healthy adults. Changes in analgesic effect after changes in infusion rate of remifentanil should be rapid and similar to those seen in young healthy adults. The pharmacokinetics of the carboxylic acid metabolite in paediatric patients 2-17 years of age are similar to those seen in adults after correcting for differences in body weight.
Elderly
The clearance of remifentanil is slightly reduced (approximately 25%) in elderly patients >65 years) compared to young patients. The pharmacodynamic activity of remifentanil increases with increasing age. Elderly patients have a remifentanil EC50 for formation of delta waves on the electroencephalogram (EEG) that is 50% lower than young patients; therefore, the initial dose of remifentanil should be reduced by 50% in elderly patients and then carefully titrated to meet the individual patient need.
5.3 Preclinical safety data
Intrathecal administration of the glycine formulation without remifentanil to dogs caused agitation, pain and hind limb dysfunction and incoordination. These effects are believed to be secondary to the glycine excipient. Glycine is a commonly used excipient in intravenous products and this finding has no relevance for intravenous administration of Remifentanyl.
Remifentanil, like other opioid agonists, produced increases in action potential duration (APD) in dog isolated Purkinje fibres. For remifentanil, the effects were seen at concentrations of 1pM or higher (which are higher than plasma concentrations seen in clinical practice). There were no effects at a concentration of 0.1pM.
The major metabolite remifentanil acid had no effect on APD up to the maximum tested concentration of 10pM.
Reproductive toxicity studies
Remifentanil has been shown to reduce fertility in male rats when administered daily by intravenous injection for at least 70 days at a dose of 0.5mg/kg, or approximately 250 times the maximum recommended human bolus dose of 2 micrograms/kg. The fertility of female rats was not affected at doses up to 1mg/kg when administered for at least 15 days prior to mating. No teratogenic effects have been observed with remifentanil at doses up to 5mg/kg in rats and 0.8mg/kg in rabbits. Administration of remifentanil to rats throughout late gestation and lactation at doses up to 5mg/kg IV had no significant effect on the survival, development, or reproductive performance of the F1 generation.
Genotoxicity
Remifentanil was devoid of genotoxic activity in bacteria and in rat liver or mouse bone marrow cells in vivo. However, a positive response was seen in vitro in different mammalian cell systems in the presence of a metabolic activation system. This activity was seen only at concentrations more than three orders of magnitude higher than therapeutic blood levels.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Glycine
Hydrochloric acid (for pH adjustment)
6.2 Incompatibilities
Remifentanil should only be admixed with those infusion solutions
recommended (see section 6.6 Instructions for use/handling).
It should not be admixed with Lactated Ringer's Injection or Lactated Ringer's and 5% Dextrose Injection.
Remifentanil should not be mixed with propofol in the same intravenous admixture solution.
For compatibility when given into a running i.v. catheter, please see section 6.6.
Administration of Remifentanil into the same intravenous line with blood/serum/plasma is not recommended. Non-specific esterases in blood products may lead to the hydrolysis of remifentanil to its inactive metabolite.
Remifentanil should not be mixed with other therapeutic agents prior to administration.
6.3 Shelf life
2 years
After reconstitution/dilution Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
6.4 Special precautions for storage
Do not store above 25°C. Keep the vial in the outer carton protected from light.
For storage conditions of the reconstituted / diluted medicinal product, see section 6.3.
6.5 Nature and contents of container
Remifentanil 2 mg Powder for Injection for intravenous use is available as 2mg of Remifentanil lyophilised powder in colourless, glass (Ph.Eur., type I) vials, closed with bromobutyl rubber (Ph.Eur., type I) stoppers and sealed with aluminium caps which have a plastic flip-off cover. Pack size of 5 vials.
6.6 Special precautions for disposal
Remifentanil should be prepared for intravenous use by adding, as appropriate 1, 2, or 5 ml of diluent to give a reconstituted solution with a concentration of 1mg/ml remifentanil. The reconstituted solution is clear, colourless, and practically free from particulate material. After reconstitution, visually inspect the product (where the container permits) for particulate material, discolouration or damage of container. Discard any solution where such defects are observed. Reconstituted product is for single use only. Any unused material should be discarded.
Remifentanil should not be administered by manually-controlled infusion without further dilution to concentrations of 20 to 250 micrograms/ml (50 micrograms/ml is the recommended dilution for adults and 20 to 25 micrograms/ml for paediatric patients aged 1 year and over).
Remifentanil should not be administered by TCI without further dilution (20 to 50 micrograms/ml is the recommended dilution for TCI).
The dilution is dependent upon the technical capability of the infusion device and the anticipated requirements of the patient.
One of the following IV fluids listed below should be used for dilution:
Water for Injections
Glucose 5% solution for injection
Glucose 5% and Sodium Chloride 0.9% solution for injection Sodium Chloride 0.9% solution for injection Sodium Chloride 0.45% solution for injection
After dilution, visually inspect the product to ensure it is clear, colourless, practically free from particulate matter and the container is undamaged. Discard any solution where such defects are observed.
Remifentanil has been shown to be compatible with the following intravenous fluids when administered into a running IV catheter:
Lactated Ringer's solution for injection
Lactated Ringer's and Glucose 5% solution for injection
Remifentanil has been shown to be compatible with propofol when administered into a running IV catheter.
The following tables give guidelines for infusion rates of Remifentanil for manually-controlled infusion:
Table 1. Remifentanil Powder for Injection Infusion Rates (ml/kg/h)
|
Drug Delivery Rate (micrograms/kg/min) |
Infusion Delivery Rate (ml/kg/h) for Solution Concentrations of | |||
|
20 micrograms /ml 1 mg/50 ml |
25 micrograms /ml 1 mg/40 ml |
50 micrograms /ml 1 mg/20 ml |
250 micrograms /ml 10 mg/40 ml | |
|
0.0125 |
0.038 |
0.03 |
0.015 |
Not recommended |
|
0.025 |
0.075 |
0.06 |
0.03 |
Not recommended |
|
0.05 |
0.15 |
0.12 |
0.06 |
0.012 |
|
0.075 |
0.23 |
0.18 |
0.09 |
0.018 |
|
0.1 |
0.3 |
0.24 |
0.12 |
0.024 |
|
0.15 |
0.45 |
0.36 |
0.18 |
0.036 |
|
0.2 |
0.6 |
0.48 |
0.24 |
0.048 |
|
0.25 |
0.75 |
0.6 |
0.3 |
0.06 |
|
0.5 |
1.5 |
1.2 |
0.6 |
0.12 |
|
0.75 |
2.25 |
1.8 |
0.9 |
0.18 |
|
1.0 |
3.0 |
2.4 |
1.2 |
0.24 |
|
1.25 |
3.75 |
3.0 |
1.5 |
0.3 |
|
1.5 |
4.5 |
3.6 |
1.8 |
0.36 |
|
1.75 |
5.25 |
4.2 |
2.1 |
0.42 |
|
2.0 |
6.0 |
4.8 |
2.4 |
0.48 |
|
Table 2. Remi |
fentanil Powder for Injection Infusion Rates (ml/ |
i) for a 20 | ||
micrograms/ml Solution
|
Infusion Rate (micrograms/kg/min) |
Patient Weight (kg) | ||||||
|
5 |
10 |
20 |
30 |
40 |
50 |
60 | |
|
0.0125 |
0.188 |
0.375 |
0.75 |
1.125 |
1.5 |
1.875 |
2.25 |
|
0.025 |
0.375 |
0.75 |
1.5 |
2.25 |
3.0 |
3.75 |
4.5 |
|
0.05 |
0.75 |
1.5 |
3.0 |
4.5 |
6.0 |
7.5 |
9.0 |
|
0.075 |
1.125 |
2.25 |
4.5 |
6.75 |
9.0 |
11.25 |
13.5 |
|
0.1 |
1.5 |
3.0 |
6.0 |
9.0 |
12.0 |
15.0 |
18.0 |
|
0.15 |
2.25 |
4.5 |
9.0 |
13.5 |
18.0 |
22.5 |
27.0 |
|
0.2 |
3.0 |
6.0 |
12.0 |
18.0 |
24.0 |
30.0 |
36.0 |
|
0.25 |
3.75 |
7.5 |
15.0 |
22.5 |
30.0 |
37.5 |
45.0 |
|
0.3 |
4.5 |
9.0 |
18.0 |
27.0 |
36.0 |
45.0 |
54.0 |
|
0.35 |
5.25 |
10.5 |
21.0 |
31.5 |
42.0 |
52.5 |
63.0 |
|
0.4 |
6.0 |
12.0 |
24.0 |
36.0 |
48.0 |
60.0 |
72.0 |
Table 3. Remifentanil Powder for Injection Infusion Rates (ml/h) for a 25 micrograms/ml Solution
|
Infusion Rate (micrograms/kg/min) |
Patient Weight (kg) | |||||||||
|
10 |
20 |
30 |
40 |
50 |
60 |
70 |
80 |
90 |
100 | |
|
0.0125 |
0.3 |
0.6 |
0.9 |
1.2 |
1.5 |
1.8 |
2.1 |
2.4 |
2.7 |
3.0 |
|
0.025 |
0.6 |
1.2 |
1.8 |
2.4 |
3.0 |
3.6 |
4.2 |
4.8 |
5.4 |
6.0 |
|
0.05 |
1.2 |
2.4 |
3.6 |
4.8 |
6.0 |
7.2 |
8.4 |
9.6 |
10.8 |
12.0 |
|
0.075 |
1.8 |
3.6 |
5.4 |
7.2 |
9.0 |
10.8 |
12.6 |
14.4 |
16.2 |
18.0 |
|
0.1 |
2.4 |
4.8 |
7.2 |
9.6 |
12.0 |
14.4 |
16.8 |
19.2 |
21.6 |
24.0 |
|
0.15 |
3.6 |
7.2 |
10.8 |
14.4 |
18.0 |
21.6 |
25.2 |
28.8 |
32.4 |
36.0 |
|
0.2 |
4.8 |
9.6 |
14.4 |
19.2 |
24.0 |
28.8 |
33.6 |
38.4 |
43.2 |
48.0 |
Table 4. Remifentanil Powder for Injection Infusion Rates (ml/h) for a 50 micrograms/ml Solution
|
Infusion Rate |
Patient Weight (kg) | |||||||
|
(micrograms/kg/min) |
30 |
40 |
50 |
60 |
70 |
80 |
90 |
100 |
|
0.025 |
0.9 |
1.2 |
1.5 |
1.8 |
2.1 |
2.4 |
2.7 |
3.0 |
|
0.05 |
1.8 |
2.4 |
3.0 |
3.6 |
4.2 |
4.8 |
5.4 |
6.0 |
|
0.075 |
2.7 |
3.6 |
4.5 |
5.4 |
6.3 |
7.2 |
8.1 |
9.0 |
|
0.1 |
3.6 |
4.8 |
6.0 |
7.2 |
8.4 |
9.6 |
10.8 |
12.0 |
|
0.15 |
5.4 |
7.2 |
9.0 |
10.8 |
12.6 |
14.4 |
16.2 |
18.0 |
|
0.2 |
7.2 |
9.6 |
12.0 |
14.4 |
16.8 |
19.2 |
21.6 |
24.0 |
|
0.25 |
9.0 |
12.0 |
15.0 |
18.0 |
21.0 |
24.0 |
27.0 |
30.0 |
|
0.5 |
18.0 |
24.0 |
30.0 |
36.0 |
42.0 |
48.0 |
54.0 |
60.0 |
|
0.75 |
27.0 |
36.0 |
45.0 |
54.0 |
63.0 |
72.0 |
81.0 |
90.0 |
|
1.0 |
36.0 |
48.0 |
60.0 |
72.0 |
84.0 |
96.0 |
108.0 |
120.0 |
|
1.25 |
45.0 |
60.0 |
75.0 |
90.0 |
105.0 |
120.0 |
135.0 |
150.0 |
|
1.5 |
54.0 |
72.0 |
90.0 |
108.0 |
126.0 |
144.0 |
162.0 |
180.0 |
|
1.75 |
63.0 |
84.0 |
105.0 |
126.0 |
147.0 |
168.0 |
189.0 |
210.0 |
|
2.0 |
72.0 |
96.0 |
120.0 |
144.0 |
168.0 |
192.0 |
216.0 |
240.0 |
|
Table 5. Remi |
entanil Powr |
er for Injection Infusion Rates (ml/h) for a 250 | ||||||
micrograms/ml Solution
|
Infusion Rate (micrograms/kg/min) |
Patient Weight (kg) | |||||||
|
30 |
40 |
50 |
60 |
70 |
80 |
90 |
100 | |
|
0.1 |
0.72 |
0.96 |
1.20 |
1.44 |
1.68 |
1.92 |
2.16 |
2.40 |
|
0.15 |
1.08 |
1.44 |
1.80 |
2.16 |
2.52 |
2.88 |
3.24 |
3.60 |
|
0.2 |
1.44 |
1.92 |
2.40 |
2.88 |
3.36 |
3.84 |
4.32 |
4.80 |
|
0.25 |
1.80 |
2.40 |
3.00 |
3.60 |
4.20 |
4.80 |
5.40 |
6.00 |
|
0.5 |
3.60 |
4.80 |
6.00 |
7.20 |
8.40 |
9.60 |
10.80 |
12.00 |
|
0.75 |
5.40 |
7.20 |
9.00 |
10.80 |
12.60 |
14.40 |
16.20 |
18.00 |
|
1.0 |
7.20 |
9.60 |
12.00 |
14.40 |
16.80 |
19.20 |
21.60 |
24.00 |
|
1.25 |
9.00 |
12.00 |
15.00 |
18.00 |
21.00 |
24.00 |
27.00 |
30.00 |
|
1.5 |
10.80 |
14.40 |
18.00 |
21.60 |
25.20 |
28.80 |
32.40 |
36.00 |
|
1.75 |
12.60 |
16.80 |
21.00 |
25.20 |
29.40 |
33.60 |
37.80 |
42.00 |
|
2.0 |
14.40 |
19.20 |
24.00 |
28.80 |
33.60 |
38.40 |
43.20 |
48.00 |
The following table provides the equivalent blood remifentanil concentration using a TCI approach for various manually-controlled infusion rates at steady state:
Table 6. Remifentanil Blood Concentrations (nanograms/ml) estimated using the Minto (1997) Pharmacokinetic Model in a 70 kg, 170 cm, 40 Year Old Male Patient for Various Manually-Controlled Infusion rates (micrograms /kg/min) at Steady State.
Remifentanil Infusion Rate
Remifentanil Blood Concentration
|
(micrograms /kg/min) |
(nanograms/ml) |
|
0.05 |
1.3 |
|
0.10 |
2.6 |
|
0.25 |
6.3 |
|
0.40 |
10.4 |
|
0.50 |
12.6 |
|
1.0 |
25.2 |
|
2.0 |
50.5 |
7 MARKETING AUTHORISATION HOLDER
Noridem Enterprises Ltd Evagorou & Makariou,
Mitsi Building 3
Office 115, 1065 Nicosia, Cyprus
8 MARKETING AUTHORISATION NUMBER(S)
PL 24598/0026
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
06/12/2011
10 DATE OF REVISION OF THE TEXT
16/08/2016